NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/29/2025
Back to search
Official data from USPTO
T
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000098585319Class
5, 9, 31, 42, 44
Filing
98585319
Registration
7774607
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
05/03/2025
Trademark type
Combined
Nice classes
5, 9, 31, 42, 44
Filing date
06/05/2024
Registration date
04/29/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/29/2025
Last transaction
05/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
99
Owner location
Cambridge, GB
Examiner
CARROLL, DORITT
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a design in the shape of a light blue puzzle piece surrounding a white letter "T".
Holders and representatives
Holders
T-Therapeutics Limited
Representatives
Stacy J. Grossman Law Office of Stacy J. Grossman PLLC
Technical classification
Nice Classes
Class 5Class 9Class 31Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment ofprotection from and prevention of viral and bacterial infectionscancerinflammationautoimmune diseases and infectious diseases; chemical and biological pharmaceutical preparations for medical purposes for the treatment ofprotection from and prevention of viral and bacterial infectionscancerinflammationautoimmune diseases and infectious diseases; biological preparations for the treatment of cancer; biological preparations for the treatment of viral infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use namelyfor the treatment ofprotection from and prevention of viral and bacterial infectionscancerinflammationautoimmune diseases and infectious diseases; immunotherapeutic drugs namelyfor the treatment ofprotection from and prevention of viral and bacterial infectionscancerinflammationautoimmune diseases and infectious diseases; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes; living cells for medical use; biological preparations for use in cell cultures for medical purposesnamely for T-cell therapygene therapy and cell therapy; biological and pharmaceutical preparations in the form of living cells for medical use in the treatment of immunological diseases; T-cell therapy pharmaceutical preparations for the treatment ofprotection from and prevention of viral and bacterial infectionscancerinflammationautoimmune diseases and infectious diseases; pharmaceutical preparations in the nature of genetically modified immune cells for the treatment of cancer
Class 9
Downloadable computer software for use in collectinganalyzing and organizing data in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering; downloadable computer software for use in collectinganalyzing and organizing data in the field of scientific and pharmaceutical research and development; downloadable software for scientific modelling of pharmaceuticals in the field of scientific and pharmaceutical research and development; downloadable software for pharmaceutical modelling in the field of scientific and pharmaceutical research and development; downloadable software for research and development in the field of antibodies; devices for analyzing genome informationlaboratory devices for detecting genetic sequences; downloadable software for performing gene sequencing research and visualizationscientific analysis of genetic sequences; downloadable software for the managinganalysisvisualization of biological data
Class 31
Live laboratory micelive transgenic mice
Class 42
Scientificmedical and technological servicesscientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for the treatment ofprotection from and prevention of infectionscancerdiseaseinflammation and autoimmune diseases; design and development of computer hardware and software; platform as a service (PAAS) featuring computer software platforms for use in database management in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering; Platform as a service (PAAS) featuring computer software platforms for DNA analysis; Platform as a service (PAAS) featuring computer software platforms for use in DNA sequencing; software as a service (SAAS) services featuring software for analyzing DNA; software as a service (SAAS) services featuring software for use in database management in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering; Providing temporary use of online non-downloadable software for the managementvisualization and analysis of biological data for the purposes of biomolecular research and the design and engineering of biomolecular products; DNA analysis services in the field of DNA sequencing for scientific research purposes; provision of a web hosting platform for the analysis of DNA sequencing data for scientific research purposes and diagnostic and treatment purposes; biomedical research services in relation to developing transgenic mice; Biomedical research servicespreparation of biological samples in the nature of living cells for analysis and research purposes; Biological analysisnamely structural and functional analysis of genomes for cell therapy and gene therapy; drug discovery services in the field of cell therapy and gene therapy; pharmaceutical drug development servicesdevelopment of gene based medicines and therapies; pharmaceutical drug development servicesdevelopment of pharmaceutical and medical preparations and medicines in the field of cell therapy and gene therapy; research in the field of gene therapy and cell therapy
Class 44
Medical services; Medical servicesnamely providing medical diagnostic and prognostic services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNAgeneticsgenetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes; mice breeding services; medical services relating to the removaltreatment and processing of living human cells; medical servicesnamely treatment and preparation of living immune cells for medical use; immune cell therapy medical treatment services; medical testing for diagnostic or treatment purposes in the field of cell therapy and gene therapy; medical analysis for diagnostic and treatment purposes and medical consulting in connection with immunotherapy; DNA analysis services in the field of DNA sequencing for diagnostic and treatment purposes
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/29/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/28/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/11/2025
PUBO
PUBLISHED FOR OPPOSITION
03/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/05/2025
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/18/2025
ALIE
ASSIGNED TO LIE
02/18/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/13/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
02/13/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/13/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
02/13/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/13/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/13/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/13/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/13/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/18/2024
GNRT
NON-FINAL ACTION E-MAILED
12/18/2024
CNRT
NON-FINAL ACTION WRITTEN
12/18/2024
DOCK
ASSIGNED TO EXAMINER
12/18/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/17/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/17/2024
NWAP
NEW APPLICATION ENTERED
06/05/2024
Continuous trademark protection
Get notified about every new filing that threatens T or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.